The Protein Phosphatase 2A pipeline drugs market research report outlays comprehensive information on the Protein Phosphatase 2A targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Protein Phosphatase 2A pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Oncology, Central Nervous System, Respiratory, and Cardiovascular which include the indications Unspecified Cancer, Solid Tumor, Alzheimer’s Disease, Epilepsy, Pulmonary Fibrosis, and Congestive Heart Failure (Heart Failure). It also reviews key players involved in Protein Phosphatase 2A targeted therapeutics development with respective active and dormant or discontinued products.

The Protein Phosphatase 2A pipeline targets constitutes close to 14 molecules. Out of which, approximately 11 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 1, 2, 3, and 5 respectively. Similarly, the universities portfolio in Phase II, and Preclinical comprises 1, and 2 molecule.

Protein Phosphatase 2A overview

Protein Phosphatase 2A (PP2A) is an enzyme encoded by the PPP2CA gene. PP2A plays important roles in regulation of cell cycle, signal transduction, cell differentiation, and transformation. Its activity is related to several diseases, including neurodegenerative diseases and cancer.

For a complete picture of Protein Phosphatase 2A’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.